[1]刘江海.异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效[J].医学信息,2019,(20):150-152.[doi:10.3969/j.issn.1006-1959.2019.20.047]
 LIU Jiang-hai.Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(20):150-152.[doi:10.3969/j.issn.1006-1959.2019.20.047]
点击复制

异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年20期
页码:
150-152
栏目:
药物与临床
出版日期:
2019-10-15

文章信息/Info

Title:
Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959(2019)20-0150-03
作者:
刘江海
(于都县人民医院医务科,江西 于都 342300)
Author(s):
LIU Jiang-hai
(Department of Medical Affairs,Yudu County People's Hospital,Yudu 342300,Jiangxi,China)
关键词:
慢阻肺急性加重期异丙托溴铵沙丁胺醇布地奈德
Keywords:
Acute exacerbation of chronic obstructive pulmonary diseaseIpratropium bromide SalbutamolBudesonide
分类号:
R563.8
DOI:
10.3969/j.issn.1006-1959.2019.20.047
文献标志码:
A
摘要:
目的 探讨沙丁胺醇与布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效。方法 选取2017年7月~2019年4月我院收治的慢阻肺急性加重期患者94例,根据随机数字表法分为观察组和对照组,每组47例。对照组给予沙丁胺醇与布地奈德雾化吸入治疗,观察组在对照组基础上加用异丙托溴铵雾化吸入治疗,比较两组临床疗效、不良反应总发生率及治疗前后肺功能指标变化情况(FEV1%、FEV1和FVC)。结果 观察组总有效率为91.49%,高于对照组的74.47%,差异有统计学意义(P<0.05)。观察组不良反应总发生率为12.76%,低于对照组的14.89%,但差异无统计学意义(P>0.05)。治疗后,观察组FEV1%、FEV1和FVC均高于对照组[(70.61±14.74)% vs(61.24±13.42)%]、[(2.25±0.77)L vs(1.94±0.63)L]、[(3.46±0.98)L vs(3.07±0.91)L],差异有统计学意义(P<0.05)。结论 沙丁胺醇与布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期患者疗效显著,有助于改善患者临床症状及肺部通气功能,减少用药后不良反应发生几率,安全性高。
Abstract:
Objective To investigate the clinical efficacy of salbutamol and budesonide combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 94 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital from July 2017 to April 2019 were enrolled. The patients were divided into observation group and control group according to the random number table method, with 47 cases in each group. The control group was given salbutamol and budesonide inhalation treatment. The observation group was treated with ipratropium bromide inhalation treatment on the basis of the control group. The clinical efficacy, the total incidence of adverse reactions and the changes of lung function indexes before and after treatment were compared between the two groups. Situation (FEV1%, FEV1 and FVC).Results The total effective rate of the observation group was 91.49%, which was higher than that of 74.47% in the control group,the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was 12.76%, which was lower than that of 14.89% in the control group, but the difference was not statistically significant (P>0.05). After treatment, FEV1%, FEV1 and FVC in the observation group were higher than those in the control group [(70.61±14.74)% vs (61.24±13.42)%], [(2.25±0.77) L vs (1.94±0.63) L], [( 3.46±0.98) L vs (3.07±0.91) L], the difference was statistically significant (P<0.05).Conclusion Salbutamol combined with budesonide and ipratropium bromide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease is effective, which can improve the clinical symptoms and pulmonary ventilation function, reduce the incidence of adverse reactions after medication, and have high safety.

参考文献/References:

[1]丁小山.布地奈德联合复方异丙托溴铵雾化吸入对慢性阻塞性肺疾病急性加重期患者的临床疗效[J]. 吉林医学,2017,38(9):1711-1712. [2]王琴,黄小红,朱齐琦.复方异丙托溴铵雾化治疗慢阻肺急性加重期患者的临床效果分析[J].中国现代医生,2017(34):104-106. [3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺病(COPD)诊治规范[J].全科医学临床与教育,2013,11(6):603-607 [4]章春花.布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期疗效分析[J].医学理论与实践,2017,30(21):3185-3186. [5]成人慢性气道疾病雾化吸入治疗专家组.成人慢性气道疾病雾化吸入治疗专家共识[J].中国呼吸与危重监护杂志,2012,11(2):105-110. [6]张凤秋.特布他林雾化液、异丙托溴铵雾化液、普米克令舒联合雾化吸入治疗慢阻肺急性加重期的疗效观察[J].中国社区医师,2018,34(32):53-54. [7]李军胜,冯娟.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效观察[J].北方药学,2016,13(3):105. [8]潘宜,黄晓颖.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国临床药理学杂志,2016,32(15):1347-1349. [9]邱彬,陈宪明.异丙托溴铵雾化吸入为主三联治疗慢阻肺急性加重期疗效观察[J].中国药师,2015,18(12):2097-2099.

相似文献/References:

[1]周 佳,柴明思.布地奈德、异丙托溴铵气雾剂联合雾化吸入治疗对肺气肿患者肺功能及血液相关指标的影响[J].医学信息,2019,(09):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
 ZHOU Jia,CHAI Ming-si.Effects of Budesonide and Ipratropium Bromide Aerosol Combined with Nebulized Inhalation on Pulmonary Function and Blood Related Indexes in Patients with Emphysema[J].Medical Information,2019,(20):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
[2]章 勇,李 秀.多索茶碱治疗慢性阻塞性肺疾病急性加重期患者的临床疗效[J].医学信息,2019,(11):159.[doi:10.3969/j.issn.1006-1959.2019.11.048]
 ZHANG Yong,LI Xiu.Clinical Efficacy of Doxofylline in the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(20):159.[doi:10.3969/j.issn.1006-1959.2019.11.048]
[3]武殿香.丙酸氟替卡松联合特布他林治疗COPD急性加重期的效果[J].医学信息,2019,(21):143.[doi:10.3969/j.issn.1006-1959.2019.21.046]
 WU Dian-xiang.Effect of Fluticasone Propionate Combined with Terbutaline on Acute Exacerbation of COPD[J].Medical Information,2019,(20):143.[doi:10.3969/j.issn.1006-1959.2019.21.046]

更新日期/Last Update: 2019-10-15